BC-CfE submitted Health Canada “Special Access Program” application to provide two investigational HIV drugs to six patients resistant to all other therapies. Health Canada denies the BC-CfE access and the BC-CfE publicly campaigns for access. Health Canada reverses its decision and the BC-CfE is first to prescribe the combination of TMC114 (darunavir) and TMC125 (etravirine) together to the remaining five patients.
BC-CfE’s research lab demonstrated the effect of impact of human and virus genetics in the response to HAART treatments.
BC-CfE launched large cohort of women in sex work to examine their sexual health and HIV needs and barriers to care.
During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.
The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)
During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service
CLICK FOR NEW HIV-1 RESISTANCE GENOTYPE REPORT NOTICE
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’. For more details and example reports, please click on the button below
